Considering Pharmaceutical Rebates—Reply-Reference-Cited by-同舟云学术

Considering Pharmaceutical Rebates—Reply

Published:2018-08-01 Issue:8 Volume:178 Page:1140
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Warraich Haider¹²,Salami Joseph A.³,Nasir Khurram⁴

Affiliation:

1. Cardiology Division, Department of Medicine, Duke University Medical Center, Durham, North Carolina

2. Duke Clinical Research Institute, Durham, North Carolina

3. Telehealth eICU, Baptist Health South Florida, Miami

4. Center for Outcomes Research and Evaluation, Section of Cardiovascular Medicine, Yale School of Medicine, Yale New Haven Health System, Yale University, New Haven, Connecticut

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Reference6 articles.

1. Generic substitution rates of oral contraceptives and associated out-of-pocket cost savings between January 2010 and December 2014.;Chee;JAMA Intern Med,2018

2. Potential savings from greater use of $4 generic drugs.;Zhang;Arch Intern Med,2011

3. Managing the challenges of pharmaceutical patent expiry: a case study of Lipitor.;Kit;J Sci Tech Policy Management,2016

4. What the PBMs aren't telling the press and employers about rebates. Pharmacy Times. December 1, 2011. http://www.pharmacytimes.com/blogs/pharmacists-united-for-truth-and-transparency/1211/what-the-pbms-arent-telling-the-press-and-employers-about-rebates. Accessed June 1, 2018.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition;PLOS ONE;2020-06-11